{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:17:13Z","timestamp":1783534633661,"version":"3.55.0"},"reference-count":39,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Atten Disord"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Although studies examining utero exposure to prescription stimulants have suggested an association with maternal and fetal adverse events, results have been inconsistent. Therefore, clinicians may not have clear guidance about stimulant use during pregnancy. The objective of this study was to evaluate maternal and fetal risks of prescription stimulant exposure among women of reproductive age throughout the continuum of pregnancy in a large, commercially insured United States population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We used a large administrative claims database from 2013 to 2021 to compare stimulant exposed pregnancies to a matched cohort of non-exposed pregnancies. Stimulant exposed pregnancies included early stimulant use, defined as one or more stimulant prescription fills at any point during the first trimester and continued exposure, defined as continuation into the second or third trimesters. Relative risk regression models were used to compare the risk of each outcome between exposure and duration of exposure cohorts matched on clinical conditions and medication used by 1:1 greedy neighbor propensity score matching.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among a sample of 10,265 matched patients, early stimulant exposure (first trimester only) was associated with a higher likelihood of live birth (RR\u2009=\u20091.08, 95% CI [1.06, 1.10]) and lower risks of spontaneous abortion (RR\u2009=\u20090.69, 95% CI [0.64, 0.76]) and preterm birth (RR\u2009=\u20090.75, 95% CI [0.62, 0.90]) compared with no stimulant exposure. Stillbirth and ectopic pregnancy did not differ. When exposure continued into the second or third trimesters, risks increased for placental abruption (RR\u2009=\u20091.63, 95% CI [1.03, 2.57]), pre-eclampsia (RR\u2009=\u20091.42, 95% CI [1.19, 1.69]), gestational hypertension (RR\u2009=\u20091.37, 95% CI [1.16, 1.61]), and preterm birth (RR\u2009=\u20091.34, 95% CI [1.12, 1.62]) compared with non-exposed pregnancies. Stillbirth was not significantly different in this comparison (RR\u2009=\u20091.42, 95% CI [0.76, 2.67]). Direct comparison of continued versus early exposure highlighted more pronounced risks with continuation: higher stillbirth (RR\u2009=\u20093.54, 95% CI [1.48, 8.44]), spontaneous abortion (RR\u2009=\u20091.53, 95% CI [1.38, 1.68]), preterm birth (RR\u2009=\u20091.86, 95% CI [1.51, 2.28]), placental abruption (RR\u2009=\u20091.78, 95% CI [1.11, 2.84]), and pre-eclampsia (RR\u2009=\u20091.33, 95% CI [1.12, 1.59]). Small-for-gestational-age infants were also more frequent in the continuation group (RR\u2009=\u20091.47, 95% CI [1.12, 1.92]). Analyses stratified by stimulant class (amphetamine vs methylphenidate containing) were directionally consistent with the overall findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Although early stimulant exposure was not associated with increases in maternal or fetal risk, our study suggests that continuation of stimulants into trimesters 2 and\/or 3 may increase some pregnancy complications including stillbirth, preterm birth, hypertensive disorders of pregnancy, and placental abruption. Clinicians should consider these risks when making the decision to continue stimulants during pregnancy, especially in treating ADHD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10870547251397034","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:38:29Z","timestamp":1765881509000},"page":"315-328","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Prescription Stimulant Continuation in Pregnancy and Birth Outcomes"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7908-7019","authenticated-orcid":false,"given":"Shaquib Al","family":"Hasan","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Care and Health Systems, University of Minnesota College of Pharmacy, Minneapolis, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena","family":"Murugappan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care and Health Systems, University of Minnesota College of Pharmacy, Minneapolis, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Westberg","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care and Health Systems, University of Minnesota College of Pharmacy, Minneapolis, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Contag","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology and Women\u2019s Health, University of Minnesota Medical School, Minneapolis, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Melnik","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Minnesota Medical School, Minneapolis, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijeet","family":"Rajpurohit","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care and Health Systems, University of Minnesota College of Pharmacy, Minneapolis, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel F.","family":"Farley","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care and Health Systems, University of Minnesota College of Pharmacy, Minneapolis, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"crossref","unstructured":"Admon L. K. Auty S. G. Daw J. R. Kozhimannil K. B. Declercq E. R. Wang N. Gordon S. H. (2023). State variation in severe maternal morbidity among individuals with Medicaid insurance. Obstetrics and Gynecology 141(5) 877\u2013885. https:\/\/doi.org\/10.1097\/AOG.0000000000005144","DOI":"10.1097\/AOG.0000000000005144"},{"key":"e_1_3_4_3_1","doi-asserted-by":"crossref","unstructured":"Ailes E. C. Simeone R. M. Dawson A. L. Petersen E. E. Gilboa S. M. (2016). Using insurance claims data to identify and estimate critical periods in pregnancy: An application to antidepressants. Birth Defects Research. Part A Clinical and Molecular Teratology 106(11) 927\u2013934. https:\/\/doi.org\/10.1002\/bdra.23573","DOI":"10.1002\/bdra.23573"},{"key":"e_1_3_4_4_1","doi-asserted-by":"crossref","unstructured":"Ananth C. V. Vintzileos A. M. (2008). Medically indicated preterm birth: Recognizing the importance of the problem. Clinics in Perinatology 35(1) 53\u201367. https:\/\/doi.org\/10.1016\/j.clp.2007.11.001","DOI":"10.1016\/j.clp.2007.11.001"},{"key":"e_1_3_4_5_1","doi-asserted-by":"crossref","unstructured":"Anderson K. N. Ailes E. C. Danielson M. Lind J. N. Farr S. L. Broussard C. S. Tinker S. C. (2018). Attention-deficit\/hyperactivity disorder medication prescription claims among privately insured women aged 15-44 years\u2014United States 2003-2015. MMWR. Morbidity and Mortality Weekly Report 67(2) 66\u201370. https:\/\/doi.org\/10.15585\/mmwr.mm6702a3","DOI":"10.15585\/mmwr.mm6702a3"},{"key":"e_1_3_4_6_1","doi-asserted-by":"crossref","unstructured":"Anderson K. N. Dutton A. C. Broussard C. S. Farr S. L. Lind J. N. Visser S. N. Ailes E. C. Shapira S. K. Reefhuis J. Tinker S. C. (2020). ADHD medication use during pregnancy and risk for selected birth defects: National birth defects prevention study 1998-2011. Journal of Attention Disorders 24(3) 479\u2013489. https:\/\/doi.org\/10.1177\/1087054718759753","DOI":"10.1177\/1087054718759753"},{"key":"e_1_3_4_7_1","doi-asserted-by":"crossref","unstructured":"Austin P. C. (2011). An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behavioral Research 46(3) 399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786","DOI":"10.1080\/00273171.2011.568786"},{"key":"e_1_3_4_8_1","doi-asserted-by":"crossref","unstructured":"Bro S. P. Kjaersgaard M. I. S. Parner E. T. S\u00f8rensen M. J. Olsen J. Bech B. H. Pedersen L. H. Christensen J. Vestergaard M. (2015). Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy. Clinical Epidemiology 7 139\u2013147. https:\/\/doi.org\/10.2147\/CLEP.S72906","DOI":"10.2147\/CLEP.S72906"},{"key":"e_1_3_4_9_1","doi-asserted-by":"crossref","unstructured":"Cao J. Zhang S. (2014). Multiple comparison procedures. JAMA 312(5) 543\u2013544. https:\/\/doi.org\/10.1001\/jama.2014.9440","DOI":"10.1001\/jama.2014.9440"},{"key":"e_1_3_4_10_1","unstructured":"Centers for Disease Control and Prevention. (2022 June 8). Data and Statistics About ADHD | CDC. https:\/\/www.cdc.gov\/ncbddd\/adhd\/data.html"},{"key":"e_1_3_4_11_1","doi-asserted-by":"crossref","unstructured":"Chomistek A. K. Phiri K. Doherty M. C. Calderbank J. F. Chiuve S. E. McIlroy B. H. Snabes M. C. Enger C. Seeger J. D. (2023). Development and validation of ICD-10-CM-based algorithms for date of last menstrual period pregnancy outcomes and infant outcomes. Drug Safety 46(2) 209\u2013222. https:\/\/doi.org\/10.1007\/s40264-022-01261-5","DOI":"10.1007\/s40264-022-01261-5"},{"key":"e_1_3_4_12_1","doi-asserted-by":"crossref","unstructured":"Chung W. Jiang S.-F. Paksarian D. Nikolaidis A. Castellanos F. X. Merikangas K. R. Milham M. P. (2019). Trends in the prevalence and incidence of attention-deficit\/hyperactivity disorder among adults and children of different racial and ethnic groups. JAMA Network Open 2(11) e1914344. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.14344","DOI":"10.1001\/jamanetworkopen.2019.14344"},{"key":"e_1_3_4_13_1","doi-asserted-by":"crossref","unstructured":"Cohen J. M. Hern\u00e1ndez-D\u00edaz S. Bateman B. T. Park Y. Desai R. J. Gray K. J. Patorno E. Mogun H. Huybrechts K. F. (2017). Placental complications associated with psychostimulant use in pregnancy. Obstetrics and Gynecology 130(6) 1192\u20131201. https:\/\/doi.org\/10.1097\/AOG.0000000000002362","DOI":"10.1097\/AOG.0000000000002362"},{"key":"e_1_3_4_14_1","doi-asserted-by":"crossref","unstructured":"Fairman K. A. Peckham A. M. Sclar D. A. (2020). Diagnosis and treatment of ADHD in the United States: Update by gender and race. Journal of Attention Disorders 24(1) 10\u201319. https:\/\/doi.org\/10.1177\/1087054716688534","DOI":"10.1177\/1087054716688534"},{"key":"e_1_3_4_15_1","unstructured":"Fingar K. R. Mabry-Hernandez I. Ngo-Metzger Q. Wolff T. Steiner C. A. Elixhauser A. (2017). Delivery hospitalizations involving Preeclampsia and Eclampsia 2005\u20132014. (Healthcare Cost and Utilization Project (HCUP) Statistical Briefs) [Internet]. Agency for Healthcare Research and Quality (US); 2006 Feb-. Table 7 ICD-9-CM diagnosis codes defining preeclampsia\/eclampsia and other types of hypertension complicating pregnancy childbirth and the puerperium. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK442039\/table\/sb222.t7\/"},{"key":"e_1_3_4_16_1","doi-asserted-by":"crossref","unstructured":"Haervig K. B. Mortensen L. H. Hansen A. V. Strandberg-Larsen K. (2014). Use of ADHD medication during pregnancy from 1999 to 2010: A Danish register-based study. Pharmacoepidemiology and Drug Safety 23(5) 526\u2013533. https:\/\/doi.org\/10.1002\/pds.3600","DOI":"10.1002\/pds.3600"},{"key":"e_1_3_4_17_1","unstructured":"Hansen L. (2018). IBM MarketScan Research Databases for life sciences researchers (pp. 1\u201316). Truven Health Ananlytics IBM Watson Health. https:\/\/www.ibm.com\/downloads\/cas\/0NKLE57Y"},{"key":"e_1_3_4_18_1","doi-asserted-by":"crossref","unstructured":"Houtchens M. K. Edwards N. C. Schneider G. Stern K. Phillips A. L. (2018). Pregnancy rates and outcomes in women with and without MS in the United States. Neurology 91(17) e1559\u2013e1569. https:\/\/doi.org\/10.1212\/WNL.0000000000006384","DOI":"10.1212\/WNL.0000000000006384"},{"key":"e_1_3_4_19_1","doi-asserted-by":"crossref","unstructured":"Huybrechts K. F. Br\u00f6ms G. Christensen L. B. Einarsd\u00f3ttir K. Engeland A. Furu K. Gissler M. Hernandez-Diaz S. Karlsson P. Karlstad \u00d8. Kieler H. Lahesmaa-Korpinen A.-M. Mogun H. N\u00f8rgaard M. Reutfors J. S\u00f8rensen H. T. Zoega H. Bateman B. T. (2018). Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations. JAMA Psychiatry 75(2) 167\u2013175. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.3644","DOI":"10.1001\/jamapsychiatry.2017.3644"},{"key":"e_1_3_4_20_1","unstructured":"Centers for Disease Control and Prevention (n.d.) ICD-10-CM. Retrieved August 18 2023 from https:\/\/icd10cmtool.cdc.gov\/?fy=FY2023"},{"key":"e_1_3_4_21_1","doi-asserted-by":"crossref","unstructured":"Jiang H.-Y. Zhang X. Jiang C.-M. Fu H.-B. (2019). Maternal and neonatal outcomes after exposure to ADHD medication during pregnancy: A systematic review and meta-analysis. Pharmacoepidemiology and Drug Safety 28(3) 288\u2013295. https:\/\/doi.org\/10.1002\/pds.4716","DOI":"10.1002\/pds.4716"},{"key":"e_1_3_4_22_1","doi-asserted-by":"crossref","unstructured":"Louik C. Kerr S. Kelley K. E. Mitchell A. A. (2015). Increasing use of ADHD medications in pregnancy. Pharmacoepidemiology and Drug Safety 24(2) 218\u2013220. https:\/\/doi.org\/10.1002\/pds.3742","DOI":"10.1002\/pds.3742"},{"key":"e_1_3_4_23_1","doi-asserted-by":"crossref","unstructured":"Montejano L. Sasan\u00e9 R. Hodgkins P. Russo L. Huse D. (2011). Adult ADHD: Prevalence of diagnosis in a US population with employer health insurance. Current Medical Research and Opinion 27 Suppl 2 5\u201311. https:\/\/doi.org\/10.1185\/03007995.2011.603302","DOI":"10.1185\/03007995.2011.603302"},{"key":"e_1_3_4_24_1","doi-asserted-by":"crossref","unstructured":"Murugappan M. N. Westberg S. M. Contag S. Melnik T. E. Kumar A. Rajpurohit A. Thorsness K. Farley J. F. (2022). Maternal ADHD and perinatal prescription stimulant use. Journal of Attention Disorders 26(10) 1347\u20131356. https:\/\/doi.org\/10.1177\/10870547211073472","DOI":"10.1177\/10870547211073472"},{"key":"e_1_3_4_25_1","unstructured":"NCQA. (2023). Prenatal and Postpartum Care (PPC). https:\/\/www.ncqa.org\/hedis\/measures\/prenatal-and-postpartum-care-ppc\/"},{"key":"e_1_3_4_26_1","doi-asserted-by":"crossref","unstructured":"Nijman T. A. J. van Vliet E. O. G. Benders M. J. N. Mol B. W. J. Franx A. Nikkels P. G. J. Oudijk M. A. (2016). Placental histology in spontaneous and indicated preterm birth: A case control study. Placenta 48 56\u201362. https:\/\/doi.org\/10.1016\/j.placenta.2016.10.006","DOI":"10.1016\/j.placenta.2016.10.006"},{"key":"e_1_3_4_27_1","doi-asserted-by":"crossref","unstructured":"N\u00f6rby U. Winbladh B. K\u00e4ll\u00e9n K. (2017). Perinatal outcomes after treatment with ADHD medication during pregnancy. Pediatrics 140(6) e20170747. https:\/\/doi.org\/10.1542\/peds.2017-0747","DOI":"10.1542\/peds.2017-0747"},{"key":"e_1_3_4_28_1","doi-asserted-by":"crossref","unstructured":"Ornoy A. Koren G. (2021). The effects of drugs used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) on pregnancy outcome and breast-feeding: A critical review. Current Neuropharmacology 19(11) 1794\u20131804. https:\/\/doi.org\/10.2174\/1570159X18666201127164000","DOI":"10.2174\/1570159X18666201127164000"},{"key":"e_1_3_4_29_1","doi-asserted-by":"crossref","unstructured":"Plessinger M. A. (1998). Prenatal exposure to amphetamines: Risks and adverse outcomes in pregnancy. Obstetrics and Gynecology Clinics of North America 25(1) 119\u2013138. https:\/\/doi.org\/10.1016\/S0889-8545(05)70361-2","DOI":"10.1016\/S0889-8545(05)70361-2"},{"key":"e_1_3_4_30_1","doi-asserted-by":"crossref","unstructured":"Poulton A. S. Armstrong B. Nanan R. K. (2018). Perinatal outcomes of women diagnosed with attention-deficit\/hyperactivity disorder: An Australian population-based cohort study. CNS Drugs 32(4) 377\u2013386. https:\/\/doi.org\/10.1007\/s40263-018-0505-9","DOI":"10.1007\/s40263-018-0505-9"},{"key":"e_1_3_4_31_1","unstructured":"SAS Institute Inc. (2018a). SAS\/STAT\u00ae 15.1 user\u2019s guide\u2014The PSMATCH procedure (pp. 8136\u20138138). https:\/\/support.sas.com\/documentation\/onlinedoc\/stat\/151\/psmatch.pdf"},{"key":"e_1_3_4_32_1","unstructured":"SAS Institute Inc. (2018b). SAS\/STAT\u00ae 15.1 user\u2019s guide\u2014The PSMATCH procedure (pp. 8179\u20138193). https:\/\/support.sas.com\/documentation\/onlinedoc\/stat\/151\/psmatch.pdf"},{"key":"e_1_3_4_33_1","doi-asserted-by":"crossref","unstructured":"Saudan P. Brown M. A. Buddle M. L. Jones M. (1998). Does gestational hypertension become pre-eclampsia? BJOG: An International Journal of Obstetrics & Gynaecology 105(11) 1177\u20131184. https:\/\/doi.org\/10.1111\/j.1471-0528.1998.tb09971.x","DOI":"10.1111\/j.1471-0528.1998.tb09971.x"},{"key":"e_1_3_4_34_1","doi-asserted-by":"crossref","unstructured":"Stek A. M. Baker R. S. Fisher B. K. Lang U. Clark K. E. (1995). Fetal responses to maternal and fetal methamphetamine administration in sheep. American Journal of Obstetrics and Gynecology 173(5) 1592\u20131598. https:\/\/doi.org\/10.1016\/0002-9378(95)90654-1","DOI":"10.1016\/0002-9378(95)90654-1"},{"key":"e_1_3_4_35_1","unstructured":"USFDA. (2022). Adderall prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/011522s044lbl.pdf#page=11"},{"key":"e_1_3_4_36_1","doi-asserted-by":"crossref","unstructured":"Visser S. N. Danielson M. L. Bitsko R. H. Holbrook J. R. Kogan M. D. Ghandour R. M. Perou R. Blumberg S. J. (2014). Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit\/hyperactivity disorder: United States 2003-2011. Journal of the American Academy of Child and Adolescent Psychiatry 53(1) 34\u201346.e2. https:\/\/doi.org\/10.1016\/j.jaac.2013.09.001","DOI":"10.1016\/j.jaac.2013.09.001"},{"key":"e_1_3_4_37_1","doi-asserted-by":"crossref","unstructured":"Walsh C. J. Rosenberg S. L. Hale E. W. (2022). Obstetric complications in mothers with ADHD. Frontiers in Reproductive Health 4 Article 1040824. https:\/\/doi.org\/10.3389\/frph.2022.1040824","DOI":"10.3389\/frph.2022.1040824"},{"key":"e_1_3_4_38_1","unstructured":"Wardinger J. E. Ambati S. (2023). Placental insufficiency. StatPearls Publishing. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK563171\/"},{"key":"e_1_3_4_39_1","doi-asserted-by":"crossref","unstructured":"Wu J.-N. Ren Y.-Y. Zhu C. Peng T. Zhang B. Li M.-Q. (2021). Abnormal placental perfusion and the risk of stillbirth: A hospital-based retrospective cohort study. BMC Pregnancy and Childbirth 21 308. https:\/\/doi.org\/10.1186\/s12884-021-03776-8","DOI":"10.1186\/s12884-021-03776-8"},{"key":"e_1_3_4_40_1","doi-asserted-by":"crossref","unstructured":"Zhang Z. Kim H. J. Lonjon G. Zhu Y. (2019). Balance diagnostics after propensity score matching. Annals of Translational Medicine 7(1) 16. https:\/\/doi.org\/10.21037\/atm.2018.12.10","DOI":"10.21037\/atm.2018.12.10"}],"container-title":["Journal of Attention Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10870547251397034","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10870547251397034","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10870547251397034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:30:45Z","timestamp":1777491045000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10870547251397034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1177\/10870547251397034"],"URL":"https:\/\/doi.org\/10.1177\/10870547251397034","relation":{},"ISSN":["1087-0547","1557-1246"],"issn-type":[{"value":"1087-0547","type":"print"},{"value":"1557-1246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]}}}